Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.72 |
| ▸ | CDK4 | P11802 | 1/20 | 0.34 |
| ▸ | CCND1 | P24385 | 1/20 | 0.34 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.30 |
| ▸ | GCK | P35557 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16078290 | 0.91 | CYP1A2 (0.77) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16072997 | 0.90 | CYP1A2 (0.70) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL23996869 | 0.90 | CYP1A2 (0.88) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16996826 | 0.89 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL20192043 | 0.88 | CYP1A2 (0.75) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL15066166 | 0.85 | CYP1A2 (0.68) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL16100045 | 0.85 | CYP2C19 (0.71) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL17501938 | 0.85 | CYP1A2 (0.80) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL18995861 | 0.85 | CYP1A2 (0.74) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 | |
| SCHEMBL17501919 | 0.84 | CYP1A2 (0.76) | CYP1A2CYP3A4CYP2C8CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422279-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275152-A1 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | CYP1A2 760/4885CYP3A4 341/4885CYP2C8 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.